Mupirocin Infectopharm (Mupirocin)

Mupirocin blocks bacterial isoleucyl‑tRNA synthetase, a key enzyme in protein synthesis. By preventing the incorporation of isoleucine into bacterial proteins, it halts bacterial growth and leads to cell death, effectively eliminating susceptible Staphylococcus aureus and Streptococcus pyogenes on the skin.

The specific dose and frequency are determined by the prescribing healthcare professional based on the severity and location of the infection, patient age, and clinical response. Patients should follow the prescriber’s instructions and the product label carefully.

Safety in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mupirocin Infectopharm.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mupirocin offers a narrow spectrum focused on Gram‑positive organisms, especially methicillin‑resistant Staphylococcus aureus (MRSA). Compared with broader‑spectrum agents like bacitracin or neomycin, mupirocin has a lower risk of cross‑allergy and is often preferred for impetigo and MRSA‑related skin infections.

Store the product at temperatures below 25 °C, in its original packaging, protected from moisture, direct sunlight and excessive heat. Do not freeze. Keeping the preparation in a cool, dry place helps maintain its stability and potency.

The medication is applied topically to the affected skin area, usually 2–3 times daily, after cleaning and gently drying the site. Use a thin layer and gently rub it in. Avoid contact with eyes, mouth and large open wounds unless directed by a clinician.

The most serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and the development of bacterial resistance if used improperly. Patients should seek immediate medical attention if they experience widespread rash, swelling, or difficulty breathing.

Individuals with a known hypersensitivity to mupirocin or any component of the formulation should avoid using the product. It is also contraindicated on extensive skin areas without medical supervision and should not be used on deep puncture wounds, animal bites, or serious burns unless directed by a healthcare professional.